Efficacy of a Potassium-Competitive Acid Blocker for Improving Symptoms in Patients with Reflux Esophagitis, Non-Erosive Reflux Disease, and Functional Dyspepsia

Asaoka, Daisuke; Nagahara, Akihito; Hojo, Mariko; Matsumoto, Kenshi; Ueyama, Hiroya; Matsumoto, Keīichi; Izumi, Kiyotaka; Takeda, Tsutomu; Kohno, Hiroyuki; Akazawa, Yoichi; Shimada, Yuji; Osada, Taro; Watanabe, Sumio

doi:10.1016/s0016-5085(17)31746-8

Cited by 3 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that the rate of symptomatic improvement of FD without VPZ or PPI treatment was 48.8%, whereas the improvements in patients administered first with VPZ and in patients resistant to 8 weeks of PPI treatment were 58.8% and 42.3%, respectively. Although the FD score was decreased after 4 weeks of VPZ therapy (p < 0.01), the response rate was remarkably lower than that in EE or NERD 20 . Hoshino et al 22 investigated the efficacy of VPZ therapy at 20 mg for 4 weeks in 24 patients with PPI-resistant EE and at 10 mg as a maintenance therapy for 8 weeks in patients who have been successfully treated.…”

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 82%

“…The rates of symptomatic improvement were 66.7% and 53.8% in patients who were administered VPZ first and in patients who were resistant to 8 weeks of PPI treatment, respectively. The VPZ treatment for 4 weeks also decreased the reflux symptom (heartburn and acid regurgitation) of NERD patients (p < 0.01), suggesting the possibility of its use as a novel therapeutic drug for NERD 20 .…”

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 87%

“…In contrast, Asaoka et al 20 investigated the efficacy of VPZ for improving the symptoms of NERD in their hospital-based, retrospective study of outpatients. The rates of symptomatic improvement were 60.0% in 25 NERD patients.…”

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 99%

“…In their retrospective study 20 , the efficacy of VPZ on the treatment of patients with FD (n = 43) was also examined. They reported that the rate of symptomatic improvement of FD without VPZ or PPI treatment was 48.8%, whereas the improvements in patients administered first with VPZ and in patients resistant to 8 weeks of PPI treatment were 58.8% and 42.3%, respectively.…”

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 99%

See 3 more Smart Citations

New pharmacological treatments for gastroesophageal reflux: Potassium-competitive acid blockers and bile acid sequestrants

Suzuki¹

2018

NGL

View full text Add to dashboard Cite

La enfermedad por reflujo gastroesofágico (ERGE) es un trastorno representativo de las enfermedades relacionadas con la acidez gastrointestinal. Para tratar estos trastornos se usan principalmente agentes antisecretores, como los inhibidores de la bomba de protones (IBP). Además de los IBP convencionales, recientemente se han desarrollado una nueva clase de agentes antiácidos, los bloqueadores de ácido competitivos de potasio (BAC-P), que actúan inhibiendo la H + /K +-ATPasa gástrica compitiendo con el K +. Por otro lado, el reflujo duodenogastroesofágico del ácido biliar es otro promotor de ERGE y sus complicaciones asociadas, como el esófago de Barrett y el adenocarcinoma esofágico inferior. Por lo tanto, los secuestradores de ácidos biliares pueden desempeñar un papel en este tipo de reflujo. En este documento se revisan las funciones de los BAC-P y los secuestradores de ácidos biliares en el tratamiento de la ERGE. Hay tres tipos de BAC-P, uno de los cuales es el vonoprazán, que tiene un potente efecto antisecretor de larga duración sobre la H + /K +-ATPasa debido a su alta acumulación y lenta eliminación en el estómago. El vonoprazán se usa actualmente en Japón para el tratamiento de la esofagitis por reflujo, induciendo un alto índice de cicatrización de la mucosa en pacientes con esofagitis por reflujo refractaria resistente a PPI, y en la protección del epitelio esofágico. Los secuestradores de ácidos biliares, como la colestiramina, se unen a los ácidos biliares y pueden ser fisiológicamente eficaces para reducir la exposición al ácido biliar de la superficie del epitelio esofágico. Mientras que actualmente los tres BAC-P tienen diferentes grados de eficacia en la terapia de la ERGE, la de los secuestradores de ácidos biliares no ha sido plenamente probada.

show abstract

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 82%

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 87%

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 99%

Section: P-cab Therapy For Non-erosive Reflux Diseases (Nerds)mentioning

confidence: 99%

See 2 more Smart Citations

New pharmacological treatments for gastroesophageal reflux: Potassium-competitive acid blockers and bile acid sequestrants

Suzuki¹

2018

NGL

View full text Add to dashboard Cite

show abstract

“…A non-randomized, controlled trial reported that 4-week treatment with vonoprazan (20 mg/day) was effective to relieve symptoms in 66.7% of NERD patients and 53.8% of PPI-resistant NERD patients. 36 In summary, 4-week treatment with vonoprazan (20 mg/ day) was effective as an initial therapy for severe erosive esophagitis (Fig. 1B), and 4-week treatment with vonoprazan and 8-week treatment with a PPI were recommended as initial therapies for mild erosive esophagitis and NERD (Fig.…”

Section: Gastroesophageal Reflux Diseasementioning

confidence: 95%

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker

Mori

Suzuki

2019

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.

show abstract

Eating Behavior in Functional Dyspepsia

Choe¹,

Song

2022

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Efficacy of a Potassium-Competitive Acid Blocker for Improving Symptoms in Patients with Reflux Esophagitis, Non-Erosive Reflux Disease, and Functional Dyspepsia

Cited by 3 publications

References 23 publications

New pharmacological treatments for gastroesophageal reflux: Potassium-competitive acid blockers and bile acid sequestrants

New pharmacological treatments for gastroesophageal reflux: Potassium-competitive acid blockers and bile acid sequestrants

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker

Eating Behavior in Functional Dyspepsia

Contact Info

Product

Resources

About